Roche has acquired ModeX Therapeutics for an undisclosed amount, strengthening its pipeline in innovative biologics for cancer and infectious diseases. ModeX Therapeutics, an OPKO Health company based in Weston, Massachusetts, specializes in developing multispecific biologics. This transaction represents a corporate acquisition, not a funding round, where Roche has directly purchased ModeX Therapeutics.
ModeX Therapeutics is a clinical-stage biopharmaceutical company developing innovative multispecific biologics for cancer and infectious disease. Its platforms unite the power of multiple biologics in a single molecule to create multispecific antibodies and vaccines with unprecedented versatility and potency in fighting complex disease. The ModeX pipeline includes candidates against both solid and liquid tumors, as well as several of the world’s most pressing viral threats. Its founding team includes globally recognized medical innovators with proven track records of delivering breakthroughs for patients.
Roche, a global leader in pharmaceuticals and diagnostics, is known for its significant contributions in oncology, immunology, and infectious diseases. This acquisition is a strategic move to integrate ModeX's advanced multispecific antibody and vaccine platforms into Roche's extensive research and development efforts. The addition of ModeX’s innovative approach, which combines multiple therapeutic mechanisms into single molecules, is expected to enhance Roche's ability to address complex diseases more effectively.
The synergy between ModeX’s platform technology and Roche’s global development and commercialization capabilities is anticipated to accelerate the progression of ModeX’s pipeline candidates. Roche aims to leverage ModeX’s scientific expertise and proprietary platforms to discover and develop next-generation therapeutics. This acquisition is set to broaden Roche's therapeutic portfolio and innovation capacity, ultimately aiming to deliver novel treatment options for patients worldwide.